TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02097992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Placebo
Description: Placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Placebo
Description: Placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Placebo
Description: Placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Placebo
Description: Placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 Ug ORAL TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 Ug ORAL TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 Ug ORAL TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 Ug ORAL TABLET
Study: NCT02671123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI with OCT with Co Registration
Description: Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronary PCI with OCT without Co Registration
Description: Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
Study: NCT00413413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg
Description: 1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: 1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg
Description: 1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Study: NCT02621164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal S1
Description: For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
Study: NCT03167294

Intervention type: DEVICE
Group type: OTHER
Intervention: AquaBeam System
Description: Aquablation
Study: NCT00906308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF101 5 g/day
Description: PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF101 10 g/day
Description: PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
Study: NCT02771340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: Intravitreal injection of ICON-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: Intravitreal injection of ICON-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: Intravitreal injection of ICON-1
Study: NCT04843501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH My Breath (CMB) program for E-cigarette prevention among adolescents
Description: CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texas Education Agency (TEA) required tobacco prevention program
Description: The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
Study: NCT01700335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-1101
Description: SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied.
Study: NCT03505606

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity tests
Description: Participants to have visual acuity tested with the three modified vision tests.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity tests
Description: Participants to have visual acuity tested with the three modified vision tests.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity tests
Description: Participants to have visual acuity tested with the three modified vision tests.
Study: NCT00764140

Intervention type: BIOLOGICAL
Intervention: tumor growth factor concentration
Description: spot urine or blood collection will be used to measure specific tumor growth factor
Study: NCT03264001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative energy balance
Description: 20% and 40% reduction of daily energy needs for weight maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative energy balance
Description: 20% and 40% reduction of daily energy needs for weight maintenance
Study: NCT04095975

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Baking Soda
Description: Standard baking soda that can be bought from stores.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LithoLyte
Description: LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
Study: NCT02049580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
Study: NCT02873104

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: truSculpt rf device
Description: radiofrequency device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: truSculpt rf device
Description: radiofrequency device
Study: NCT01416805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy
Description: Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
Study: NCT02049580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study: NCT00669110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Description: * tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)
Study: NCT01964391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy
Description: Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
Study: NCT01827085

Intervention type: DEVICE
Intervention: Conventional Macintosh laryngoscope

Intervention type: DEVICE
Intervention: Stortz videolaryngoscope
Study: NCT03170271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab (Medi-563)
Description: 30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
Study: NCT02799485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT04469868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No opioids at discharge
Description: Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues.
Study: NCT00700037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose atorvastatin
Description: 20mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose atorvastatin
Description: 5mg/day
Study: NCT01416805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
Study: NCT02257411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ear-sized based
Description: the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
Study: NCT03335839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator
Description: Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
Study: NCT02708745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Survey

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Survey
Study: NCT03335839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator
Description: Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT06101719

Intervention type: DIAGNOSTIC_TEST
Intervention: Enteral contrast challenge
Description: Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
Study: NCT03069690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABITpreg
Description: Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABITpreg
Description: Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020.
Study: NCT00946556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valacyclovir
Description: 1g po od for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 1g po od for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po od for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo po od for 2 months
Study: NCT00736138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: training and pellots
Description: training and pellots
Study: NCT03361540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: ASP8302 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT02976129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing of placebo three times a day orally for 6 weeks
Study: NCT03707405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ride-On Cars Training with Different Postures
Description: All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
Study: NCT03069690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABITpost
Description: Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABITpost
Description: Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020.
Study: NCT00079547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie diet
Description: low-calorie diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-carbohydrate diet
Description: low-carbohydrate diet
Study: NCT03009110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic NPWT
Description: The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
Study: NCT04596878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to Alhydrogel as an adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to Alhydrogel as an adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9%

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9%